Immunotherapy has unleashed a revolution in care for some cancer patients. But most immunotherapies help only a small subset of patients, meaning doctors often have to resort to a trial-and-error process to determine who might actually benefit from the novel treatments.

Now, scientists have developed a new metric they believe can help predict whether patients will respond to a class of immunotherapies known as checkpoint inhibitors, drugs that train the body’s natural defenses on cancer cells.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The elephant in the room is a scientific question never asked: Why are neo-antigens important and predictive in the first place?
    A tumor of a size that can be imaged an attracts immune cells consists of around 10^9 to 10^10 cells. Neo-antigens are by definition not necessary driver proteins, but any protein in the proteome that is randomly mutated. Hence each given neo-antigen need not be enriched in these gazillions of cancer cells (this is the strength/weakness of immunotherapy: it is not restricted to targeting the causative mechanism). So, a given neo-antigen is always expressed in just a tiny subfraction of these gazillions of cells in the tumor – as recent sub-regional and single-cell analysis has shown.

    Why then does immunotherapy directed at specific neo-antigen work in the first place?

    There is this leap of faith at the core of immunotherapy. One way to reconcile this is to assume “antigen-spreading” – so far more hand-waving than well-documented. Another is to assume innocent bystander killing.

    Perhaps the ability of transcriptomes/proteome information for prediction reflects the potency of promoting anti-gen-spreading and innocent bystander effect???

  • Dear Stat News,

    I highly encourage you to contact Genocea regarding their ATLAS Neoantigen ID Platform for cancer immunotherapy and to discuss GEN-009 & GEN-011.

    Thanks,

    Allen Brzozowski

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy